<DOC>
	<DOCNO>NCT01699711</DOCNO>
	<brief_summary>Epigallocatechin-3-gallate ( EGCG ) , major catechin green tea , postulated modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A ( DYRK1A ) amyloid beta precursor protein ( APP ) gene overexpression brain Down syndrome mouse model . The clinical study aim demonstrate normalization Dyrk1A APP function therapeutic approach improve cognitive performance decelerate AD ( Alzheimer 's disease ) like progression .</brief_summary>
	<brief_title>Normalization dyrk1A APP Function Approach Improve Cognitive Performance Decelerate AD Progression DS Subjects : Epigallocatechin Gallate Therapeutic Tool</brief_title>
	<detailed_description />
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Have diagnose DS neurological disease , age 1429 year . Have give consent participate ( official custody ) . Subjects neurological disease DS , relevant medical disease , comorbid mental disorder currently take treatment could interfere cognitive function alter key biomarkers biochemical parameter analyze . Having suffer major illness undergo major surgery last three month study . Regular ingestion medication month precede study ( exception single dos symptomatic medication administer week precede trial ) . Current ingestion vitamin supplement catechins AINE two week precede study . History gastrointestinal , hepatic renal problem cause may alter process absorption , distribution , metabolism , excretion drug , might suggest gastrointestinal irritation drug . Subjects follow vegetarian diet . Practice physical exercise 2 hour per day energy consume/consumption 3000 kcal per week .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>APP function ( amyloid precursor protein , cognitive stimulation , alzheimer disease . program</keyword>
</DOC>